95% of cancer drugs fail in human trials
after being tested in animals
Prof. Valerie Speirs and the colleagues at the University of Aberdeen, UK developed a fully humanized, 3D perfused breast cancer model. In a study published in PLoS One, they show how perfusion and hemoglobin-like oxygen delivery influence breast cancer (BC) growth and responses to a commonly used drug, tamoxifen:
Validation of a 3D perfused cell culture platform as a tool for humanised preclinical drug testing in breast cancer using established cell lines and patient-derived tissues
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0283044
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0283044
Patient-derived, ER-positive breast cancer models are difficult to establish in mice. Typically, the engraftment rate is lower than 15% which limits the number of models that can be used in research.
Perfused Organ Panel successfully supported the growth of all tested primary BC tissues and enabled long-term drug testing in vitro. Perfused tissues had higher metabolic activity, ranging from 2.3-fold (case 2724) to 1.3-fold (case 1756) compared to static BC cultures. Tumor heterogeneity between the patient samples leads to patient- and sample-specific drug responses which were captured under perfused conditions.
Perfused Organ Panel successfully supported the growth of all tested primary BC tissues and enabled long-term drug testing in vitro. Perfused tissues had higher metabolic activity, ranging from 2.3-fold (case 2724) to 1.3-fold (case 1756) compared to static BC cultures. Tumor heterogeneity between the patient samples leads to patient- and sample-specific drug responses which were captured under perfused conditions.
Unperfused tumor models in vitro model an early disease stage,
a tumor which the patient had when the tumor formed
a tumor which the patient had when the tumor formed
For drug efficacy and personalized/precision therapies, it is critically important to model a tumor which the patient has at a time of drug treatment, rather than the tumor which the patient had at an earlier disease phase.
Early-stage tumors, lacking blood vessel invasion, exist in a nutrient-starved state. Without perfusion, they remain tiny and necrotic with new cells replacing dying cells. This is not the tumor which most patients have during drug treatment which is why early tumor models are a dead end for testing anti-cancer drugs and optimizing the patients' therapy.
For accurate drug efficacy testing, we must model vascularized, perfused tumors - a growing mass of cells with access to blood vessels which patients have at treatment. Lena Biosciences Perfused Organ Panel deliver this critical, clinically relevant model.
Early-stage tumors, lacking blood vessel invasion, exist in a nutrient-starved state. Without perfusion, they remain tiny and necrotic with new cells replacing dying cells. This is not the tumor which most patients have during drug treatment which is why early tumor models are a dead end for testing anti-cancer drugs and optimizing the patients' therapy.
For accurate drug efficacy testing, we must model vascularized, perfused tumors - a growing mass of cells with access to blood vessels which patients have at treatment. Lena Biosciences Perfused Organ Panel deliver this critical, clinically relevant model.
Lena Biosciences Perfused Organ Panel models tumors the patients have now
Because most tumors bigger than 1-2 mm in diameter are perfused with blood which provides nutrients and oxygen required for tumor growth and metastasis, Perfused Organ Panel provides more accurate model of the patient's tumor for his or her therapy optimization.
Perfused Organ Panel models vascularized and perfused tumors
that patients have at the time of drug treatment
Read the article
that patients have at the time of drug treatment
Read the article
